SG#INBIORC2610B

NTES-S

KWAN YONG

PEIJIA-B

REMEGEN

RADIANCE HLDGS

POP MART

BAOZUN-W

ARCHOSAUR GAMES

XIAOCAIYUAN

HEPALINK

159615

SBIO

159506

517110

159837

159570

516820

513120

159859

513060

560600

159892

589720

516500

512010

159992

01801

516930

512290

Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel

Tip Ranks

China Southern Hang Seng Biotech ETF(QDII)

ALPS Medical Breakthrough

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

ICBCCS SSE STAR Biology and Medicine ETF

Takeda Pharmaceutical Company

iShares Global Healthcare

E Fund CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng Health Care ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

First Trust NYSE Arca Biotech Index Fd

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

SPDR S&P Biotech

Guotai SSE STAR Brand Name Drug ETF

Invesco Biotechnology & Genome ETF

Takeda Pharmaceutical Co. Ltd.

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Invesco Nasdaq Biotechnology ETF

Huaan Hang Seng Biotech ETF

INNOVENT BIO

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

iShares Biotechnology ETF

VG Health

VanEck Biotech ETF

iShares US Pharma

Ark Genomic Revolution ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel

The global weight-loss drug market is evolving with new oral options and competitive pricing. Novo Nordisk has launched the first GLP-1 pill for obesity, prompting other companies like Eli Lilly, Structure Therapeutics, Merck, AstraZeneca, Roche, Viking Therapeutics, and Pfizer to develop their own oral obesity drugs. Eli Lilly's orforglipron shows significant weight loss in trials, while Pfizer has entered the market through acquisition. Other companies, including Innovent Biologics and HuaDong Pharmaceutical, are also testing their oral GLP-1 candidates. The market is projected to be worth $150 billion in the next decade.

- The global weight-loss drug market is evolving with the introduction of oral options and falling prices, prompting Wall Street to revise its $150 billion forecast.  
- Key players, including Eli Lilly and Novo Nordisk, are now facing competition from several companies developing their own oral GLP-1 agonists for obesity treatment.  
- Among these, Eli Lilly's orforglipron, Structure Therapeutics' GSBR-1290, and Pfizer's acquisition of Metsera are noteworthy developments in this competitive landscape.

Reuters

Viking Therap

Novo Nordisk AS

Eli Lilly

Defiance Daily Target 2X Long NVO ETF

Health Care Select Sector SPDR

AstraZeneca

Structure Therapeutics

Pfizer

Direxion Daily LLY Bull 2X Shares

Proshares Ultra Nasdaq Biotech

Roche

Merck

Defiance Daily Target 2X Long LLY ETF

ROCHE HOLDINGS AG

FACTBOX-Top pharma companies racing to launch a weight-loss pill

09618

00175

09961

02714

06869

01913

02600

03993

01378

JD-SW(09618) rose 9.95%, with a trading turnover 5.1 Billion HKD, and a year-to-date fell 4.5%. GEELY AUTO(00175) rose 7.92%, with a trading turnover 1.2 Billion HKD, and a year-to-date fell 8.6%. YOFC(06869) fell 7.79%, with a trading turnover 3.9 Billion HKD, and a year-to-date rose 167.9%. PRADA(01913) fell 5.76%, with a trading turnover 206.3 Million HKD, and a year-to-date fell 9.2%.

- The Hang Seng Index increased by 1.72%, with a year-to-date gain of 0.5%, while the Hang Seng Tech Index rose by 3.15%, but has declined by 10.3% this year.  
- JD.com saw a notable increase of 9.95% with a trading volume of 5.06 billion HKD, yet it remains down 4.5% year-to-date, while Geely Automobile rose by 7.92% with a trading volume of 1.21 billion HKD, down 8.6% in 2026.  
- In contrast, Longxing Optical Fiber Cable fell by 7.79% despite a trading volume of 3.87 billion HKD, maintaining a significant year-to-date gain of 167.9%, whereas Prada dropped by 5.76% with a trading volume of 210 million HKD, marking a 9.2% decline this year.

Top Gainers & Losers

JD-SW

GEELY AUTO

TRIP.COM-S

MUYUAN

YOFC

PRADA

CHALCO

CMOC

CHINAHONGQIAO

Top 5 HK Stock Gainers/Losers (>100B) (3.6)

09988

09896

00700

Hong Kong stocks closed mixed: the Hang Seng Index rose 0.28% to 25,321.34, the Tech Index fell 0.69% to 4,796.33, and the National Enterprises Index fell 0.38% to 8,451.43. The technology internet and energy sectors weakened, with Alibaba down 2.77% and Tencent down 0.79%, dragging the market; the top trading volumes were Alibaba at HKD 1,811,139.75 thousand, Tencent at HKD 1,216,376.63 thousand, and China National Offshore Oil Corporation at HKD 589,461.73 thousand, with overall sentiment being neutral to cautious

- On March 5, 2026, the three major indices showed mixed results, with a cautious market sentiment and short-term focus on overcoming earlier highs. 
- The Hang Seng Index closed up by 0.28% at 25,321.34 points, while the Hang Seng Tech Index fell by 0.69% to 4,796.33 points, reflecting a pullback from previous highs. 
- Key sectors like oil and gas faced pressure, and major stocks such as Alibaba and Tencent experienced declines, emphasizing an increase in cautious market behavior.

Market Heartbeat

BABA-W

MNSO

TENCENT

KUAISHOU-W

BIDU-SW

CNOOC

UNITEDENERGY GP

CHK OIL

GIGADEVICE

JIAXIN INTL RES

COSCO SHIP HOLD

Hong Kong Stock Market Closing | Hang Seng Index rose 0.28%, Tech Index fell 0.69%, AIA Group rose 5.06%

The three major indices of the Hong Kong stock market showed divergence during the trading session: the Hang Seng Index rose slightly by 0.17% to 25,291.29 points, the Hang Seng Tech Index fell by 0.90% to 4,786.12 points, and the National Enterprises Index decreased by 0.44% to 8,446.62 points, all failing to break through their respective recent highs. In terms of sectors, retailers are under pressure, internet content and information show divergence, and oil and gas exploration and production are fluctuating. Among the leaders, Alibaba weakened, Tencent showed weakness, while China National Offshore Oil Corporation strengthened. In terms of trading volume, Alibaba, Tencent, and China National Offshore Oil Corporation are at the forefront, with activity concentrated in heavyweight and energy technology stocks, and market sentiment is cautious

- The Hong Kong stock market shows mixed performance, with the Hang Seng Index slight increase of 0.17% at 25,291.29 points, while the technology sector declines 0.90%.  
- Retail sector faces pressure from earnings reports with Alibaba down 3.16% and JD down 1.07%, indicating sector volatility ahead of reports.  
- Market focus remains cautious amidst macroeconomic indicators, including U.S. Treasury rates and indicators on domestic consumption and trade, with significant activity seen in top energy and technology stocks.

WEICHAI POWER

Hong Kong stock market intraday | The Hang Seng Index rose slightly by 0.17%, the Tech Index fell by 0.90%, and CNOOC rose by 1.11%

08189

02561

09688

Morgan Stanley released a research report listing the investment ratings and target prices for Chinese biopharmaceutical stocks. The rating for Genscript Biotech is in line with the market, with the target price lowered from 55 yuan to 44 yuan; the rating for Innovent Bio is to overweight, with a target price of 130 yuan; the rating for Visen Pharma-B is to overweight, with the target price lowered from 80 yuan to 50 yuan; the rating for Zai Lab is to overweight, with the target price lowered from 37.5 yuan to 19.5 yuan

AASTOCKS

TEDA BIOMEDICAL

VISEN PHARMA-B

ZAI LAB

Morgan Stanley's investment ratings and target prices for Chinese biopharmaceutical stocks (Table)

Morgan Stanley released a report stating that the Chinese biotechnology sector has entered a turning point this year, with stable fundamentals, strong resilience in innovation, and a recovery in financing activities. It is expected to be volatile in the first half of the year, with unstable risk appetite; in the second half, stock price direction will become clearer due to catalysts and capital reallocation. Morgan Stanley has resumed coverage of INNOVENT BIO, giving it an "Overweight" rating and a target price of 130 yuan, while adjusting the target prices of several other stocks

Morgan Stanley: Catalysts for China's biotech sector concentrated in the second half, reinitiating coverage on INNOVENT BIO with an "Overweight" rating

Innovent Biologics, Inc. announced that its non-covalent Bruton's tyrosine kinase inhibitor, Jaypirca® (pirtobrutinib), has received approval from the National Medical Products Administration in China for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma after prior systemic therapy. This approval is based on the Phase 3 BRUIN CLL-321 study, which showed significant improvements in progression-free survival and lower treatment-related discontinuation rates compared to existing therapies. The approval marks a significant advancement for patients with relapsed or refractory CLL/SLL in China.

marketscreener

Innovent Biologics, Inc. Announces the Non-Covalent Bruton's Tyrosine Kinase Inhibitor, Jaypirca®? (Pirtobrutinib) Receives Approval by the National Medical Products Administration

INNOVENT BIO announced that the non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor Jepalitumab (Pirtobrutinib) has officially been approved by the National Medical Products Administration of China for a new indication, to be used in the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including a BTK inhibitor

INNOVENT BIO's match-patent for Bruton’s tyrosine kinase inhibitor has received official approval for new indications

688235

06160

03692

Hong Kong-listed Chinese pharmaceutical companies are poised for profitability due to rising drug sales and lucrative licensing deals. Innovent Biologics expects its first full-year profit of 984 million yuan in 2025, driven by a 45% revenue increase. BeOne reported a net profit of US$286.93 million, fueled by its successful blood cancer drug Brukinsa. Other firms like Jiangsu Hengrui and Hansoh Pharma are also projected to see significant profit growth. The trend of out-licensing early-stage drugs to global firms is strengthening, with investors increasingly interested in China's healthcare sector.

SCMP

BeOne Medicines

BEONE MEDICINES

HANSOH PHARMA

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Innovent Biologics says Jaypirca received approval by NMPA China

Innovent Biologics says Jaypirca received approval by NMPA China

SPDB analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$110.00.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential In addition to SPDB, Innovent Biologics also received a Buy from Bernstein’s Rebecca Liang in a report issued on February 9. However, on February 4, TipRanks – OpenAI reiterated a Hold rating on Innovent Biologics (Other OTC: IVBXF).

Innovent Biologics (IVBXF) Gets a Buy from SPDB

8604

Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy

Nomura Holdings, Inc.

Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

RemeGen

WUXI BIO

WuXi Biologics

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

SG#INBIORC2610B(55708.HK)

Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel

FACTBOX-Top pharma companies racing to launch a weight-loss pill

Top 5 HK Stock Gainers/Losers (>100B) (3.6)

Hong Kong Stock Market Closing | Hang Seng Index rose 0.28%, Tech Index fell 0.69%, AIA Group rose 5.06%

Hong Kong stock market intraday | The Hang Seng Index rose slightly by 0.17%, the Tech Index fell by 0.90%, and CNOOC rose by 1.11%